Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Treatment of Male Androgenetic Alopecia: Current and Emerging Therapies
Description
The talk reviewed current and emerging treatments for male androgenetic alopecia, emphasizing that although the condition is biologically complex—involving androgens, fibrosis, inflammation, and microcirculation—approved therapies remain finasteride and minoxidil. Oral minoxidil was presented as effective and often faster-acting than topical formulations, but it should be started at low doses because of potential adverse effects such as edema, hypertrichosis, and interactions with antihypertensive drugs. Oral antiandrogens were discussed with particular attention to sexual side effects and possible neuropsychiatric effects, including concerns about mood changes and postfinasteride syndrome, which remains controversial but warrants monitoring. The speaker noted that topical options, including minoxidil, finasteride compounded formulations, and topical antiandrogens, can be useful, though oral minoxidil may be more practical for adherence. Emerging and adjunctive therapies included intralesional antiandrogens such as dutasteride, combination approaches pairing oral and intralesional treatment, PRP, low-level laser therapy, and experimental options like exosomes and newer molecules targeting follicular biology. The talk also highlighted the importance of considering overlapping conditions such as lichen planopilaris, nutritional and thyroid factors, GLP-1 medications, and discussing hair transplantation early. The overall message was that combination therapy, early intervention, and future targeting of fibroblasts and WNT signaling are likely to shape management.
View moreConclusions
- Oral minoxidil appears to be an effective and relatively safe option for male androgenetic alopecia, with low-dose titration recommended to balance benefit and adverse effects.
- Compared with topical therapy, oral minoxidil may improve adherence and may act faster, making it an increasingly favored first-line choice in practice.
- Oral antiandrogens such as finasteride and dutasteride remain important treatments, but sexual and neuropsychiatric adverse effects require careful counseling and monitoring.
- The presentation emphasizes that post-finasteride syndrome remains controversial, yet clinicians should still actively screen for sexual dysfunction and mental health symptoms.
- Combination therapy is emerging as the standard approach rather than relying on single agents, especially when combining oral, topical, and procedural treatments.
- Topical therapies, including topical finasteride and topical antiandrogen combinations, can be effective but are mainly used to reduce systemic exposure or address patient preference.
- Intralesional antiandrogens, particularly dutasteride, are presented as promising off-label options, with repeated sessions every few months suggested for maintenance.
- PRP and low-level laser therapy may serve as useful adjuncts, with newer wavelengths and protocols showing potential improvements in hair thickness and follicular outcomes.
- Exosomes and newer investigational molecules are promising but remain unapproved, so they are best viewed as future or experimental options rather than current standards.
- Treatment planning should account for comorbid scalp disorders, nutritional status, thyroid disease, and medication effects such as GLP-1 therapies.
- Hair transplantation should be discussed early and reserved for patients with stable alopecia and adequate donor supply, ideally as part of a pre- and post-treatment strategy.
- Overall, early intervention and follicle-focused combination therapy are presented as the key future direction for managing androgenetic alopecia.
- Dias et al. Frontiers in Pharmacology, 2026.
- Larios-Cárdenas M, Quiñones-Hernández DG, León Quintero-Loreto M, Grover-Páez F, Moreno-Alanis JA, Quiñones-Hernández R, Calderón-Quiroz ER, et al. Comparative efficacy of oral dutasteride and low-, medium-, and high-dose oral minoxidil: a six-month prospective trichoscopic and clinical study. Front Med. 2026;13:1751116.#10.3389/fmed.2026.1751116
- Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatol Treat. 2022 Jun;33(4):1896-1906.#10.1080/09546634.2021.1945527
- Gupta AK, Talukder M, and Williams G. Journal of Dermatological Treatment, 2022.
- Koralewicz MM, Szatkowska OA. Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatol. 2024;10(3):71-78.#10.5603/fd.101208
- Mahawar B, Deshmukh AR. Randomized controlled trial to compare the efficacy of oral minoxidil 1.25 mg versus 2.5 mg versus topical 5% minoxidil in androgenetic alopecia. Dermatol Sin. 2026;44(1):37-43.#10.4103/ds.ds-d-25-00094
- Chen S, Li L, Ding W, Zhu Y, Zhou N. Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment. Drug Des Devel Ther. 2025 Aug 25;19:7349-7363.#10.2147/dddt.s542000
- Frontiers in Medicine article: 675nm Diode Laser as an adjuvant Treatment for Telogen Effluvium: case series.#10.3389/fmed.2026.1753577
- International expert consensus statement focusing on pre and post hair transplantation care.#10.1080/09546634.2023.2232065
- Spanish hair disorders group consensus statement.